{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:25Z","timestamp":1779955585859,"version":"3.53.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapy for axial spondyloarthritis (axSpA), improving pain, function, and disease activity. This review evaluates evidence for NSAID efficacy, potential disease modification, and safety considerations in patients with axSpA, particularly those with inflammatory bowel disease (IBD) or elevated cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Evidence for NSAID-mediated disease modification remains inconsistent. In patients with IBD, contemporary data suggest variable risk of disease exacerbation depending on NSAID selectivity and exposure patterns. Established gastrointestinal toxicities persist outside the IBD context, though risk-mitigation strategies are available. While general-population studies demonstrate increased cardiovascular risk with certain NSAIDs, emerging axSpA-specific observational data suggest a smaller excess risk of major adverse cardiovascular events, potentially reflecting the counterbalancing effect of inflammation control. Pharmacogenomic data increasingly support CYP2C9 variation as a determinant of NSAID exposure and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>NSAIDs remain foundational in axSpA management, but long-term use requires individualized assessment of gastrointestinal, cardiovascular, and IBD-related risks. Pharmacogenomic considerations may further refine patient selection and dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001164","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:01:07Z","timestamp":1779955267000},"page":"225-231","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Choosing NSAID treatment in axial spondyloarthritis: factors guiding clinical decision-making"],"prefix":"10.1097","volume":"38","author":[{"given":"Lianne S.","family":"Gensler","sequence":"first","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailean E.","family":"McKay","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack"},{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3899\/jrheum.150721","article-title":"Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a cochrane Review","volume":"43","author":"Kroon","year":"2016","journal-title":"J Rheumatol"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of nonsteroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1093\/rheumatology\/keaf393","article-title":"Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis","volume":"64","author":"Hwang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard-2023-224699","article-title":"Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2\u200ayears in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial","volume":"83","author":"Proft","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","article-title":"Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis","volume":"72","author":"Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fmed.2019.00214","article-title":"Nonsteroidal anti-inflammatory drugs are unlikely to inhibit radiographic progression of ankylosing spondylitis: a systematic review","volume":"6","author":"Zhang","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ecco-jcc\/jjae022","article-title":"Peripheral joint and enthesis involvement in patients with newly diagnosed inflammatory bowel disease: symptoms, and clinical and ultrasound findings \u2013 a population-based cohort study","volume":"18","author":"Vladimirova","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14309\/ajg.0000000000003039","article-title":"Spine and sacroiliac joint involvement in newly diagnosed patients with inflammatory bowel disease: clinical and MRI findings from a population-based cohort","volume":"120","author":"Vladimirova","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/S0002-9343(98)00071-0","article-title":"Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs","volume":"105","author":"Cryer","year":"1998","journal-title":"Am J Med"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10620-006-3103-5","article-title":"Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs","volume":"51","author":"Meyer","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/gut.40.5.619","article-title":"Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease","volume":"40","author":"Evans","year":"1997","journal-title":"Gut"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.14309\/ajg.0000000000001932","article-title":"The association between nonsteroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias?","volume":"117","author":"Cohen-Mekelburg","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1572-0241.2000.02263.x","article-title":"Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease","volume":"95","author":"Bonner","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/ph8030512","article-title":"Use of cyclo-oxygenase inhibitors is not associated with clinical relapse in inflammatory bowel disease: a case-control study","volume":"8","author":"Hensley","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/apt.14606","article-title":"Systematic review and meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and Risk of Crohn's disease and ulcerative colitis exacerbation","volume":"47","author":"Moninuola","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MCG.0000000000000421","article-title":"Role of non-steroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease","volume":"50","author":"Long","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00054725-200411000-00009","article-title":"A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease","volume":"10","author":"Bonner","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R30-20260528","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0090-6980(98)00064-1","article-title":"The advent of highly selective inhibitors of cyclooxygenase \u2013 a review","volume":"56","author":"Cryer","year":"1998","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"R31-20260528","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R32-20260528","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-20260528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R34-20260528","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"R35-20260528","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2036.2008.03706.x","article-title":"National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use","volume":"28","author":"Abraham","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-20260528","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"R37-20260528","first-page":"728","article-title":"Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R38-20260528","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1111\/j.1572-0241.2008.02200.x","article-title":"First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Antiplatelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Antiplatelet Agents","volume":"103","author":"Chan","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"(Suppl4)","key":"R39-20260528","doi-asserted-by":"crossref","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","article-title":"Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Zhao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R40-20260528","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-022-06473-9","article-title":"Cardiovascular comorbidities in spondyloarthritis","volume":"42","author":"Bodur","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R41-20260528","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s10067-023-06655-z","article-title":"Cardiovascular risk in axial spondyloarthritis-a systematic review","volume":"42","author":"Hintenberger","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R42-20260528","doi-asserted-by":"crossref","first-page":"152037","DOI":"10.1016\/j.semarthrit.2022.152037","article-title":"Factors associated with atherosclerosis in radiographic and nonradiographic axial spondyloarthritis. a multicenter study on 838 patients","volume":"55","author":"Rueda-Gotor","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R43-20260528","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1038\/s41598-022-11640-8","article-title":"Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis","volume":"12","author":"Navarini","year":"2022","journal-title":"Sci Rep"},{"key":"R44-20260528","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R45-20260528","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00296-025-05975-4","article-title":"Cardiovascular risk in axial spondyloarthritis: the interplay of inflammation, traditional risk factors, and management strategies","volume":"45","author":"Issakulova \u0410","year":"2025","journal-title":"Rheumatol Int"},{"key":"R46-20260528","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists\u2019 (CNT) Collaboration","year":"2013","journal-title":"Lancet"},{"key":"R47-20260528","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jcph.1302","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs and classical and selective cyclooxygenase-2 inhibitors: a meta-analysis of observational studies","volume":"59","author":"Mart\u00edn Arias","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R48-20260528","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/rheumatology\/kead072","article-title":"Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study","volume":"62","author":"Fakih","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R49-20260528","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semarthrit.2019.07.012","article-title":"Nonsteroidal anti-inflammatory drugs and cardiovascular risk \u2013 a matter of indication","volume":"50","author":"Braun","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R50-20260528","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/03009742.2025.2467556","article-title":"Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and nonselective nonsteroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study","volume":"54","author":"Kim","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"R51-20260528","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/acr.22555","article-title":"Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a swedish national population-based cohort study","volume":"67","author":"Kristensen","year":"2015","journal-title":"Arthritis Care Res"},{"key":"R52-20260528","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/rheumatology\/kead684","article-title":"Risk of cardiovascular disease associated with long-term use of nonsteroidal anti-inflammatory drugs in ankylosing spondylitis","volume":"64","author":"Kim","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R53-20260528","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/ard-2023-225406","article-title":"Risk of cardiovascular disease with high-dose versus low-dose use of nonsteroidal anti-inflammatory drugs in ankylosing spondylitis","volume":"83","author":"Kim","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R55-20260528","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"R56-20260528","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","article-title":"Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis","volume":"157","author":"Becker","year":"2009","journal-title":"Am Heart J"},{"key":"R57-20260528","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jacc.2018.02.036","article-title":"Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen","volume":"71","author":"Reed","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R58-20260528","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","article-title":"Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism","volume":"44","author":"Kim","year":"2021","journal-title":"Arch Pharm Res"},{"key":"R59-20260528","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s12272-021-01361-3","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes","volume":"44","author":"Cho","year":"2021","journal-title":"Arch Pharm Res"},{"key":"R60-20260528","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jcph.169","article-title":"Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib","volume":"53","author":"Prieto-P\u00e9rez","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R61-20260528","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s12272-022-01388-0","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism","volume":"45","author":"Cho","year":"2022","journal-title":"Arch Pharm Res"},{"key":"R62-20260528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R63-20260528","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12272-016-0861-2","article-title":"Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite","volume":"40","author":"Kim","year":"2017","journal-title":"Arch Pharm Res"},{"key":"R64-20260528","doi-asserted-by":"crossref","first-page":"113926","DOI":"10.1016\/j.fct.2023.113926","article-title":"Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen","volume":"178","author":"Yuan","year":"2023","journal-title":"Food Chem Toxicol"},{"key":"R65-20260528","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","article-title":"Polymorphisms of human cytochrome P450 2C9 and the functional relevance","volume":"278","author":"Zhou","year":"2010","journal-title":"Toxicology"},{"key":"R66-20260528","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.105.006452","article-title":"Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?","volume":"33","author":"Rodrigues","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R67-20260528","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences","volume":"17","author":"Zhou","year":"2023","journal-title":"Hum Genomics"},{"key":"R68-20260528","doi-asserted-by":"crossref","first-page":"1597379","DOI":"10.3389\/fphar.2025.1597379","article-title":"Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice","volume":"16","author":"Biswas","year":"2025","journal-title":"Front Pharmacol"},{"key":"R70-20260528","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17425250902970998","article-title":"Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?","volume":"5","author":"Ag\u00fandez","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R71-20260528","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2007.05.025","article-title":"Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms","volume":"133","author":"Pilotto","year":"2007","journal-title":"Gastroenterology"},{"key":"R72-20260528","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/17425255.2020.1744563","article-title":"An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding","volume":"16","author":"Mac\u00edas","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R73-20260528","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/FPC.0000000000000186","article-title":"CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study","volume":"26","author":"Figueiras","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"R74-20260528","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1038\/s41467-025-61644-x","article-title":"Clinical impact of pharmacogenetic risk variants in a large Chinese cohort","volume":"16","author":"Wei","year":"2025","journal-title":"Nat Commun"},{"key":"R75-20260528","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s12913-021-07025-8","article-title":"Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation","volume":"21","author":"Turongkaravee","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"R76-20260528","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-016-0397-9","article-title":"A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions","volume":"34","author":"Plumpton","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"R77-20260528","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","article-title":"Pharmacogenomics","volume":"394","author":"Roden","year":"2019","journal-title":"Lancet"},{"key":"R78-20260528","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"R79-20260528","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41397-025-00376-z","article-title":"Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States","volume":"25","author":"Patel","year":"2025","journal-title":"Pharmacogenomics J"},{"key":"R80-20260528","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cpt.3736","article-title":"Progress in pharmacogenomics implementation in the united states: barrier erosion and remaining challenges","volume":"118","author":"Smith","year":"2025","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:01:18Z","timestamp":1779955278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001164","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}